Explore the Efficacy and Mechanism of Action of Tezepelumab in Eosinophilic Granulomatosis With Polyangiitis

To be considered for this study, you need to be an adult between 18 and 75 years old with EGPA. Your doctor will confirm your EGPA diagnosis based on specific medical findings, such as a history of asthma, high levels of certain white blood cells (eosinophils), and other symptoms or test results that are typical of EGPA.

Additionally, you must have experienced active EGPA recently. This means you’ve either had a flare-up of your EGPA in the last two years that required an increase in your medication, or your current treatments haven't quite brought your condition fully under control. Your doctor will also check your blood test results for specific cell counts.

It's important to remember that this study is not for everyone, and the research team will check all these detailed criteria to make sure it's the right fit for you. Even if you meet some of these points, your full medical history will be reviewed to ensure your safety in the study.

If you decide to take part in this study, you'll be involved for a total of 24 weeks. During this time, you will visit one of 12 study centres across the UK. You will receive the study medication (either tezepelumab or a placebo) as an injection under the skin every four weeks. All participants will continue to take their usual EGPA medications, including steroid tablets, throughout the study.

The research team will closely monitor your EGPA. This will involve regular check-ups, blood tests, and assessments of your symptoms, such as your asthma control, and nose and sinus health. The aim is to see if your steroid dose can be gradually lowered safely during the study. There will also be evaluations of your breathing using a simple test called spirometry. You'll have regular contact with the study team who will support you throughout your participation.